Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant.
We have shown that intranasal coapplication of Bacillus anthracis protective Ag (PA) together with a B. anthracis edema factor (EF) mutant having reduced adenylate cyclase activity (i.e., EF-S414N) enhances anti-PA Ab responses, but also acts as a mucosal adjuvant for coadministered unrelated Ags. To elucidate the role of edema toxin (EdTx) components in its adjuvanticity, we examined how a PA mutant lacking the ability to bind EF (PA-U7) or another mutant that allows the cellular uptake of EF, but fails to efficiently mediate its translocation into the cytosol (PA-dFF), would affect EdTx-induced adaptive immunity. Native EdTx promotes costimulatory molecule expression by macrophages and B lymphocytes, and a broad spectrum of cytokine responses by cervical lymph node cells in vitro. These effects were reduced or abrogated when cells were treated with EF plus PA-dFF, or PA-U7 instead of PA. We also intranasally immunized groups of mice with a recombinant fusion protein of Yersinia pestis F1 and LcrV Ags (F1-V) together with EdTx variants consisting of wild-type or mutants PA and EF. Analysis of serum and mucosal Ab responses against F1-V or EdTx components (i.e., PA and EF) revealed no adjuvant activity in mice that received PA-U7 instead of PA. In contrast, coimmunization with PA-dFF enhanced serum Ab responses. Finally, immunization with native PA and an EF mutant lacking adenylate cyclase activity (EF-K346R) failed to enhance Ab responses. In summary, a fully functional PA and a minimum of adenylate cyclase activity are needed for EdTx to act as a mucosal adjuvant.
Department of Veterinary Biosciences, Ohio State University, Columbus, OH 43210, USA.
Alexandra
A
Duverger
Jeanne-Marie
JM
Carré
Junbae
J
Jee
Stephen H
SH
Leppla
Estelle
E
Cormet-Boyaka
Wei-Jen
WJ
Tang
Daniel
D
Tomé
Prosper N
PN
Boyaka
D000262:Adenylyl Cyclases / Q000378:metabolism; D000276:Adjuvants, Immunologic / Q000378:metabolism*; D000281:Administration, Intranasal; D000818:Animals; D000881:Anthrax / Q000276:immunology* / Q000378:metabolism; D022122:Anthrax Vaccines / Q000276:immunology; D000942:Antigens, Bacterial / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism; D001408:Bacillus anthracis / Q000276:immunology; D001427:Bacterial Toxins / Q000276:immunology* / Q000378:metabolism; D002469:Cell Separation; D005260:Female; D005434:Flow Cytometry; D018928:Immunity, Mucosal / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D020133:Reverse Transcriptase Polymerase Chain Reaction
D000276:Adjuvants, Immunologic; D022122:Anthrax Vaccines; D000942:Antigens, Bacterial; D001427:Bacterial Toxins; C030325:anthrax toxin; D000262:Adenylyl Cyclases